lasofoxifene
Phase 3- Indications
- ER+/HER2- metastatic breast cancer, Ovarian cancer
Company intelligence / Profile preview
Sermonix Pharmaceuticals
Columbus, Ohio, United Statessermonixpharma.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 3
01
Overview
Sermonix’s lead candidate, lasofoxifene, has demonstrated promising anti-tumor activity in patients with metastatic ER+/HER2-, ESR1-mutated breast cancer. In the ELAINE clinical trials, lasofoxifene as monotherapy showed numerically longer progression-free survival than fulvestrant in heavily pre-treated patients. The combination of lasofoxifene and abemaciclib achieved a median progression-free survival of approximately 13 months in this population. A global registrational Phase 3 trial (ELAINE‑3) began enrollment in December 2023[8][6].
- Therapeutic areas
- Oncology
- Modalities
- Small moleculesSelective Estrogen Receptor Modulators (SERMs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sermonix Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sermonix Pharmaceuticals.